Oruka Therapeutics, Inc. financial data

Symbol
ORKA on Nasdaq
Location
855 Oak Grove Ave., Suite 100, Menlo Park, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.45K % +1.16%
Debt-to-equity 3.96 % -39.9%
Return On Equity -27.1 % +57%
Return On Assets -26 % +37%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48.4M shares +38.3%
Common Stock, Shares, Outstanding 48.4M shares +38.2%
Entity Public Float 39.7M USD +89.8%
Common Stock, Value, Issued 48K USD +37.1%
Weighted Average Number of Shares Outstanding, Basic 42.1M shares +1216%
Weighted Average Number of Shares Outstanding, Diluted 42.1M shares +1216%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 104M USD +132%
General and Administrative Expense 18.8M USD +80%
Operating Income (Loss) -122M USD -122%
Nonoperating Income (Expense) 16.3M USD +363%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -107M USD -97.7%
Earnings Per Share, Basic 2 USD/shares +93.4%
Earnings Per Share, Diluted 2 USD/shares +93.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 91.3M USD -77.8%
Marketable Securities, Current 258M USD
Other Assets, Current 537K USD -10.4%
Assets, Current 355M USD -14%
Property, Plant and Equipment, Net 253K USD +58.1%
Operating Lease, Right-of-Use Asset 1.97M USD +110%
Other Assets, Noncurrent 103K USD +140%
Assets 509M USD +23%
Accounts Payable, Current 571K USD +137%
Employee-related Liabilities, Current 109K USD -42.6%
Liabilities, Current 21M USD +16.2%
Operating Lease, Liability, Noncurrent 1.49M USD +77.3%
Liabilities 22.5M USD +19%
Accumulated Other Comprehensive Income (Loss), Net of Tax 185K USD
Retained Earnings (Accumulated Deficit) -160M USD -175%
Stockholders' Equity Attributable to Parent 487M USD +42.2%
Liabilities and Equity 509M USD +23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9M USD -1266%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 545M shares 0%
Common Stock, Shares, Issued 48.4M shares +38.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.53M USD +4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 91.3M USD -77.8%
Deferred Tax Assets, Valuation Allowance 21.3M USD -61.6%
Deferred Tax Assets, Gross 21.5M USD -61.3%
Operating Lease, Liability 1.91M USD +93.5%
Depreciation 16K USD
Payments to Acquire Property, Plant, and Equipment 13K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -101M USD -5.04%
Lessee, Operating Lease, Liability, to be Paid 2.33M USD +78.6%
Property, Plant and Equipment, Gross 222K USD -3.06%
Operating Lease, Liability, Current 419K USD +187%
Lessee, Operating Lease, Liability, to be Paid, Year Two 768K USD +55.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 822K USD +123%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 421K USD +32.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 397K USD +4.47%
Deferred Tax Assets, Operating Loss Carryforwards 2.26M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.05M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 304K USD
Operating Lease, Payments 63K USD +174%
Additional Paid in Capital 643M USD +61.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 63K USD -29.2%
Share-based Payment Arrangement, Expense 25.2M USD +154%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%